These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30469350)

  • 21. Industry experiences with immune-mediated findings in biotherapeutic nonclinical toxicology studies.
    MacLachlan TK; Kronenberg S; Marshall N; Andrews L; Berens SJ; Brouta F; Fogal B; Freebern W; Herzyk D; Kamperschroer C; Kiessling A; Schneidkraut M; Maier C
    Regul Toxicol Pharmacol; 2021 Feb; 119():104825. PubMed ID: 33220389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Engineering therapeutic antibodies for patient safety: tackling the immunogenicity problem.
    Ulitzka M; Carrara S; Grzeschik J; Kornmann H; Hock B; Kolmar H
    Protein Eng Des Sel; 2020 Sep; 33():. PubMed ID: 33128053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monoclonal Antibodies: Past, Present and Future.
    Posner J; Barrington P; Brier T; Datta-Mannan A
    Handb Exp Pharmacol; 2019; 260():81-141. PubMed ID: 31820172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Theoretical considerations and practical approaches to address the effect of anti-drug antibody (ADA) on quantification of biotherapeutics in circulation.
    Kelley M; Ahene AB; Gorovits B; Kamerud J; King LE; McIntosh T; Yang J
    AAPS J; 2013 Jul; 15(3):646-58. PubMed ID: 23543601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Affimers as anti-idiotypic affinity reagents for pharmacokinetic analysis of biotherapeutics.
    Adamson H; Nicholl A; Tiede C; Tang AA; Davidson A; Curd H; Wignall A; Ford R; Nuttall J; McPherson MJ; Johnson M; Tomlinson DC
    Biotechniques; 2019 Dec; 67(6):261-269. PubMed ID: 31823668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biologics and anaphylaxis.
    Sala-Cunill A; Luengo O; Cardona V
    Curr Opin Allergy Clin Immunol; 2019 Oct; 19(5):439-446. PubMed ID: 31169597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity assay development and validation for biological therapy as exemplified by ustekinumab.
    Mojtahed Poor S; Ulshöfer T; Gabriel LA; Henke M; Köhm M; Behrens F; Geisslinger G; Parnham MJ; Burkhardt H; Schiffmann S
    Clin Exp Immunol; 2019 May; 196(2):259-275. PubMed ID: 30656642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New monoclonal antibodies in renal transplantation.
    Vincenti F
    Minerva Urol Nefrol; 2003 Mar; 55(1):57-66. PubMed ID: 12773967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Immunogenicity of Biologic Therapies.
    Garcês S; Demengeot J
    Curr Probl Dermatol; 2018; 53():37-48. PubMed ID: 29131036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020.
    Jawa V; Terry F; Gokemeijer J; Mitra-Kaushik S; Roberts BJ; Tourdot S; De Groot AS
    Front Immunol; 2020; 11():1301. PubMed ID: 32695107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioanalytical Challenges due to Prior Checkpoint Inhibitor Exposure: Interference and Mitigation in Drug Concentration and Immunogenicity Assays.
    Dengler AF; Weiss R; Truong T; Irvin SC; Gadhia N; Hassanein M; Georgaros C; Taylor JA; Paccaly A; Sumner G; Andisik MD; Torri A; Partridge MA
    AAPS J; 2021 Oct; 23(6):109. PubMed ID: 34608545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets.
    Martin PL; Bugelski PJ
    Br J Pharmacol; 2012 Jun; 166(3):806-22. PubMed ID: 22168335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mitigation of Pre-existing Antibodies to a Biotherapeutic in Non-clinical Species When Establishing Anti-drug Antibody Assay Cutpoint.
    Kumar SC; DelCarpini JA; Qu Q; Kane M; Gorovits B
    AAPS J; 2017 Jan; 19(1):313-319. PubMed ID: 27873117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel immune check point inhibiting antibodies in cancer therapy-Opportunities and challenges.
    Diesendruck Y; Benhar I
    Drug Resist Updat; 2017 Jan; 30():39-47. PubMed ID: 28363334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current Considerations on Characterization of Immune Response to Multi-Domain Biotherapeutics.
    Gorovits B; Peng K; Kromminga A
    BioDrugs; 2020 Feb; 34(1):39-54. PubMed ID: 31641991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development.
    Sauna ZE; Jawa V; Balu-Iyer S; Chirmule N
    Front Immunol; 2023; 14():1151888. PubMed ID: 37251396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Licensed monoclonal antibodies and associated challenges.
    Khan AH; Sadroddiny E
    Hum Antibodies; 2015 Dec; 23(3-4):63-72. PubMed ID: 27472864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets.
    Bugelski PJ; Martin PL
    Br J Pharmacol; 2012 Jun; 166(3):823-46. PubMed ID: 22168282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developments in therapy with monoclonal antibodies and related proteins.
    Shepard HM; Phillips GL; D Thanos C; Feldmann M
    Clin Med (Lond); 2017 Jun; 17(3):220-232. PubMed ID: 28572223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Posttranslational Modifications and the Immunogenicity of Biotherapeutics.
    Jefferis R
    J Immunol Res; 2016; 2016():5358272. PubMed ID: 27191002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.